Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.35 -5.3%	$7.30	$5.90 ▼ $30.31	$536.48M	2.17	1.50 million shs	1.54 million shs
PGEN Precigen	$1.76 -3.3%	$1.51	$0.65 ▼ $2.17	$537.23M	1.78	1.48 million shs	1.98 million shs
THTX Theratechnologies	$3.14 -0.3%	$2.68	$1.12 ▼ $3.20	$144.38M	0.55	898,727 shs	355,140 shs
TYRA Tyra Biosciences	$10.39 -4.3%	$9.89	$6.42 ▼ $29.60	$576.56M	1.07	291,903 shs	104,279 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	-5.28%	-5.65%	-1.61%	-14.53%	-76.43%
PGEN Precigen	-3.30%	-3.83%	+18.12%	+26.62%	+1.73%
THTX Theratechnologies	0.00%	-0.32%	+25.60%	+24.60%	+104.56%
TYRA Tyra Biosciences	-4.33%	+1.27%	+9.37%	+16.48%	-48.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	3.9297 of 5 stars	4.3	4.0	0.0	0.0	2.1	2.5	1.3
PGEN Precigen	4.0694 of 5 stars	3.5	0.0	0.0	4.7	3.9	1.7	0.6
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	3.1743 of 5 stars	3.5	5.0	0.0	0.0	1.6	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$20.29	176.05% Upside
PGEN Precigen	3.00	Buy	$6.00	240.91% Upside
THTX Theratechnologies	3.00	Buy	N/A	N/A
TYRA Tyra Biosciences	3.00	Buy	$30.83	196.76% Upside

Current Analyst Ratings Breakdown

Latest THTX, TYRA, PGEN, and ARVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/15/2025	ARVN Arvinas	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$74.00 ➝ $21.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/9/2025	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$12.00 ➝ $11.00
5/5/2025	ARVN Arvinas	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.50

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$426.90M	1.26	N/A	N/A	$8.17 per share	0.90
PGEN Precigen	$3.92M	132.53	N/A	N/A	$0.13 per share	13.54
THTX Theratechnologies	$84.38M	1.71	N/A	N/A	($0.61) per share	-5.15
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$0.66	N/A	N/A	N/A	-10.92%	-7.74%	-4.11%	7/29/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
THTX Theratechnologies	-$8.31M	-$0.19	N/A	44.86	N/A	-10.85%	N/A	-9.83%	N/A
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/6/2025 (Estimated)

Latest THTX, TYRA, PGEN, and ARVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	PGEN Precigen	-$0.14	N/A	N/A	N/A	$0.67 million	N/A
8/6/2025	Q2 2025	TYRA Tyra Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
7/29/2025	Q2 2025	ARVN Arvinas	-$0.87	N/A	N/A	N/A	$34.42 million	N/A
7/9/2025	Q2 2025	THTX Theratechnologies	-$0.01	-$0.09	-$0.08	-$0.09	$24.30 million	$17,729.00 billion
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/1/2025	Q1 2025	ARVN Arvinas	-$0.93	$1.14	+$2.07	$1.14	$41.87 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	4.58	4.58
PGEN Precigen	N/A	3.53	3.53
THTX Theratechnologies	N/A	0.84	0.65
TYRA Tyra Biosciences	N/A	22.78	22.78

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
PGEN Precigen	33.51%
THTX Theratechnologies	N/A
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
PGEN Precigen	47.10%
THTX Theratechnologies	N/A
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	72.99 million	69.54 million	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable

THTX, TYRA, PGEN, and ARVN Headlines

Recent News About These Companies

Tyra Biosciences (NASDAQ:TYRA) Trading Up 5.7% - Should You Buy?

July 16 at 1:00 PM | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.9% - What's Next?

July 15, 2025 | marketbeat.com

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Morningstar

July 9, 2025 | morningstar.comM

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

July 8, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 3.3% - What's Next?

July 3, 2025 | marketbeat.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC

July 2, 2025 | targetedonc.comT

Tyra Biosciences begins patient dosing in phase 2 study of TYRA-300 in low-grade intermediate risk non-muscle invasive bladder cancer

July 1, 2025 | pharmabiz.comP

Tyra Biosciences' (TYRA) "Buy" Rating Reiterated at HC Wainwright

July 1, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Rating of "Buy" by Brokerages

July 1, 2025 | marketbeat.com

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)

June 30, 2025 | prnewswire.com

Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 5.6% - Here's What Happened

June 23, 2025 | marketbeat.com

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of Stock

June 21, 2025 | insidertrades.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $93,575.04 in Stock

June 20, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in Stock

June 17, 2025 | insidertrades.com

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025 | prnewswire.com

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

May 9, 2025 | finance.yahoo.com

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025 | prnewswire.com

Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%

May 6, 2025 | aaii.comA

Tyra Biosciences price target lowered to $28 from $29 at BofA

March 30, 2025 | markets.businessinsider.com

Tyra Biosciences reports Q4 EPS (43c) vs. (53c) last year

March 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

THTX, TYRA, PGEN, and ARVN Company Descriptions

Arvinas NASDAQ:ARVN

$7.35 -0.41 (-5.28%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.40 +0.05 (+0.68%)

As of 07/18/2025 06:11 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Precigen NASDAQ:PGEN

$1.76 -0.06 (-3.30%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.79 +0.03 (+1.70%)

As of 07/18/2025 07:53 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Theratechnologies NASDAQ:THTX

$3.14 -0.01 (-0.32%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.14 +0.00 (+0.16%)

As of 07/18/2025 04:39 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Tyra Biosciences NASDAQ:TYRA

$10.39 -0.47 (-4.33%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$10.20 -0.19 (-1.82%)

As of 07/18/2025 06:11 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time